UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2006

CYCLACEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

0-50626 (Commission File Number)

91-1707622 (IRS Employer Identification No.)

150 John F. Kennedy Parkway, Suite 100 Short Hills, NJ 07078 (Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (973) 847-5955

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Item 2.02 Results of Operations and Financial Condition

The information set forth under this "Item 2.02. Results of Operations and Financial Condition", including the exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Attached as Exhibit 99.1 is a copy of a press release of Cyclacel Pharmaceuticals, Inc., dated November 13, 2006, announcing certain financial results for its fiscal third quarter ended September 30, 2006.

Item 9.01 Financial Statements and Exhibits

The following exhibit is furnished with this report:

Exhibit No. 99.1

Description

Press Release dated November 13, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYCLACLEL PHARMACEUTICALS, INC.

/s/ Paul McBarron

Name: Paul McBarron

Title: Executive Vice President, Finance & Chief Operating Officer

Date: November 13, 2006



PRESS RELEASE

CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS

Short Hills, NJ, November 13, 2006 — Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) today reported financial and operating results for the third quarter 2006. The company had a net loss in the quarter of \$5.4 million. At the end of the third quarter 2006, the company had \$59.7 million in cash, cash equivalents and marketable securities.

"The progress of our lead clinical candidates, seliciclib and sapacitabine, remained in line with our key development milestones, and we strengthened our management team with the addition of John Womelsdorf as Vice President, Business Development," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. "We achieved important progress in this quarter with seliciclib, our lead drug, by initiating the APPRAISE randomized, double-blinded Phase IIb study in patients with Non-Small Cell Lung Cancer or NSCLC. Data from APPRAISE is anticipated in late 2007. In addition, we are considering expanding the range of indications addressed by seliciclib by assessing the feasibility of developing the drug as a treatment for nasopharyngeal cancer, or NPC. At present there are no approved medicines for the treatment of NPC and our evaluation suggests that this is an area of great medical need. Current treatments, principally chemotherapy combined with radiotherapy, produce high initial response rates, but there is a high mortality rate after relapse. We expect to provide more details on our plans for NPC in the coming months."

"We have also been making steady progress with sapacitabine, our second drug. We have been conducting Phase I studies in patients with solid tumors as well as advanced leukemias and myelodysplastic syndromes. Data from both of these studies will be reported in the fourth quarter. Our plan is to enter into Phase II clinical development with this compound in one or more cancer indications in 2007," noted Mr. Rombotis. "Finally, CYC116, our Aurora kinase and VEGFR2 inhibitor, remains on track for an IND filing before the end of the year."

Other key highlights from the quarter include:

- In October, the Company strengthened its management team with the appointment of John Womelsdorf, Ph.D., to the position of Vice President, Business Development. Dr. Womelsdorf has more than 20 years of experience in business development roles at Baxter International, Hoffmann-La Roche, and, most recently, Johnson & Johnson (J&J), where he served as Executive Director, Licensing and New Business Development of the Pharmaceuticals Group.
- The Company remains on track with enrolment of the Phase IIb, multi-center, randomized, double-blinded APPRAISE trial which is evaluating the efficacy and safety of the investigational drug seliciclib (CYC202), an orally available molecule that targets cyclin dependent kinases (CDKs), as a third-line treatment in patients with non-small cell lung cancer (NSCLC).

The study is co-chaired by Chandra P. Belani, M.D., Professor of Medicine and Co-Director of the Lung and Thoracic Program at the University of Pittsburgh Cancer Institute in Pittsburgh, PA and Alan B. Sandler, M.D., Associate Professor of Medicine at the Vanderbilt-Ingram Cancer Center in Nashville, TN. Approximately 160 patients from 20 centers in the United States will participate in the study. The trial's primary efficacy endpoint is progression free survival. Secondary endpoints include overall survival, response rate, response duration, safety and tolerability. The study employs a randomized discontinuation design. All patients will receive seliciclib for at least three

150 JFK Parkway, Suite 100, Short Hills, New Jersey 07078, USA Tel +1 (973) 847 5955 Fax +1 (866) 271 3466
 Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067

 $\underline{www.cyclacel.com} - \underline{info@cyclacel.com}$

treatment cycles. Patients who achieve stable disease after three cycles will be randomized to continue on seliciclib or receive placebo with best supportive care. Patients in the placebo group whose disease progresses will be given the option to cross-over and receive seliciclib treatment again.

• The Company has also reported that the Phase I clinical trial of sapacitabine (CYC682), an orally available nucleoside analog, in patients with advanced leukemias or myelodysplastic syndromes (MDS) continues on schedule. The study is being led by Dr. Hagop Kantarjian, Chairman of the Department of Leukemia at The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston. The study's primary objective is to determine the maximum tolerated dose of sapacitabine in patients with advanced leukemias or MDS. The study's secondary objectives are to characterize the pharmacodynamic effects of sapacitabine in tumor cells, evaluate the relationship between pharmacokinetics and pharmacodynamics, and correlate the pharmacodynamic effects of sapacitabine with anti-cancer activity. The pharmacologic part of the study is led by Dr. William Plunkett, Chief of Cellular and Molecular Pharmacology at UTMDACC. The trial will involve approximately 30 patients. Update on the progress of this trial will be reported in the 4th quarter of 2006.

Key Financials

The net loss applicable to ordinary shareholders according to U.S. generally accepted accounting principles (GAAP) for the quarter ended September 30, 2006 was \$5.4 million, or \$0.34 per share (including \$0.3 million, or \$0.016 per share of non-cash stock-based compensation expense) as compared to \$5.9 million, or \$0.77 per share in the third quarter of 2005.

Research and development (R&D) expenses were \$4.1 million in the third quarter of 2006, which included \$0.2 million of non-cash stock-based compensation expense, as compared to \$2.9 million in the third quarter of 2005, which included a credit of \$0.7 million of non-cash stock-based compensation. The \$0.3 million increase in R&D expenses, excluding stock-based compensation, was primarily due to activities related to the IND-directed studies for CYC116

About seliciclib and sapacitabine

Seliciclib is an orally available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets that are central to the process of cell division and cell cycle control. Seliciclib has been administered to more than 200 patients to date, and it is currently being evaluated in a Phase IIb randomized discontinuation trial ("APPRAISE") as a third-line treatment in patients with non-small cell lung cancer (NSCLC).

Sapacitabine is an oral nucleoside analog prodrug that acts through a dual mechanism that is unique among nucleoside analogs. It interferes with DNA synthesis by causing single-strand DNA breaks and induces arrest of the cell cycle. Sapacitabine has been administered to approximately 144 patients to date. It has undergone three

Phase I studies in patients with solid tumors and lymphomas, and is currently being evaluated in a Phase I clinical trial in patients with advanced leukemias or myelodysplastic syndromes (MDS).

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The Company is currently evaluating seliciclib (CYC202), an orally-available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer. Sapacitabine (CYC682) is an orally-available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of cancer. CYC116 is an orally-available, Aurora kinase inhibitor in IND-directed preclinical development. Several additional programs are at an earlier stage.

Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results

2

expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Forms S-3 (File No. 333-134945) and S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC.

Contacts for Cyclacel:

For Investors: TS Communications Group, LLC Tara Spiess (914) 921-5900 For Media: Feinstein Kean Healthcare Kate Weiss (617) 577-8110

Period from

3

CYCLACEL PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Paris Pari		For the three months ended September 30,		For the nine months ended September 30,		August 13, 1996 (inception) to September 30,
Revenues: Collaboration and research and development revenue 27 102 152 168 2,911 Grant revenue 56 57 118 118 3,438 Operating expenses:(1) Research and development (4,059) (2,932) (17,196) (12,095) (117,966) General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expenses): Costs associated with aborted 2004 IPO — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52)		2006				2006
Collaboration and research and development revenue 27 102 152 168 2,911 Grant revenue 56 57 118 118 3,438 Operating expenses:(1) Research and development (4,059) (2,932) (17,196) (12,095) (117,966) General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 1 1 <th>D</th> <th></th> <th>\$000, except</th> <th>per share and shar</th> <th>re amounts</th> <th></th>	D		\$000, except	per share and shar	re amounts	
development revenue 27 102 152 168 2,911 Grant revenue 56 57 118 118 3,438 Operating expenses:(I) Research and development (4,059) (2,932) (17,196) (12,095) (117,966) General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 IPO — — — — (162) — (162) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest income 657						
Grant revenue 56 57 118 118 3,438 Roperating expenses:(I) Research and development (4,059) (2,932) (17,196) (12,095) (117,966) General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,465) (14,931) Operating loss (6,795) (3,917) (26,877) (15,465) (14,918) Operating loss (6,795) (3,917) (26,877) (15,465) (144,918) Operating loss (6,712) (3,758) (26,607) (15,465) (144,918) Other income (expense): — — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) — (162) Interest income 793 196 1,565 604 7,844		27	102	150	160	2.011
Operating expenses: (1) (4,059) (2,932) (17,196) (12,095) (117,966) General and advelopment (4,059) (2,932) (17,196) (12,095) (117,966) General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 — — — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) 3,840 Total other income (expense) 677 181 1,225 550 292						
Operating expenses:(1) Research and development (4,059) (2,932) (17,196) (12,095) (117,966) General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 IPO — — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (14,639)	Grant revenue					
Research and development (4,059) (2,932) (17,196) (12,095) (117,096) General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 IPO — — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,9	Onewating expenses (1)	0.3	159	270	200	0,349
General and administrative (2,511) (985) (9,456) (3,656) (33,089) Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 IPO — — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (144,639) Net loss (5,432) (2,976) (23,723) (13,409)		(4.050)	(2.022)	(17 106)	(12.00E)	(117.066)
Other restructuring costs (225) — (225) — (225) Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 IPO — — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (14,4639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss applicable to ordinary shares — (2,967) (2,827) (8,910)<	•					
Total operating expenses (6,795) (3,917) (26,877) (15,751) (151,280) Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 IPO — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (144,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss applicable to ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary share- basic and diluted (5,432) (5,943) (2			(903)		(3,030)	
Operating loss (6,712) (3,758) (26,607) (15,465) (144,931) Other income (expense): Costs associated with aborted 2004 IPO — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (144,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary shares (5,432) (5,943) (26,550) <t< td=""><td></td><td></td><td>(2.017)</td><td></td><td>(15.751)</td><td></td></t<>			(2.017)		(15.751)	
Other income (expense): Costs associated with aborted 2004 — — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (144,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary share-basic and diluted (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted (0.34) (0.37) (0.77) (0.77)						
Costs associated with aborted 2004 — — — — — (3,550) Change in valuation of derivative Interest income (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (14,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary shares (5,432) (5,943) (26,550) (22,319) (17,0,863) Net loss per share – basic and diluted (0.34) (0.07) (3,077) (26,550) (22,319) (17,0,863)	Operating 1033	(0,712)	(3,730)	(20,007)	(13,403)	(144,331)
IPO — — — — (3,550) Change in valuation of derivative (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (14,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary — (5,432) (5,943) (26,550) (22,319) (17,0,863) Net loss per share – basic and diluted (0.34) (0.07) (3,077) (2,070) (2,070) (2,070) (2,070) (2,070) (2,070)	Other income (expense):					
Change in valuation of derivative Interest income (64) — (162) — (162) Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (144,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary shares (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted (0.34) (0.77) (2.07) (2.28) (2.28)	Costs associated with aborted 2004					
Interest income 793 196 1,565 604 7,844 Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (14,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary shares (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted (0.34) (0.77) (2.07) (2.08) (2.08)		_	_	_	_	(3,550)
Interest expense (52) (15) (178) (54) (3,840) Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (14,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary share-basic and diluted (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share-basic and diluted (0.34) (0.77) (2,077) (2,087) (2,087)	Change in valuation of derivative	(64)	_	(162)	_	(162)
Total other income (expense) 677 181 1,225 550 292 Loss before taxes (6,035) (3,577) (25,382) (14,915) (144,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary share- basic and diluted (5,432) (5,943) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted (0.34) (0.77) (2.07) (2.08)	Interest income	793	196	1,565	604	7,844
Loss before taxes (6,035) (3,577) (25,382) (14,915) (144,639) Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary share-basic and diluted (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted (0.34) (0.77) (20,77) (2.82) (2.88)	Interest expense	(52)	(15)	(178)	(54)	(3,840)
Income tax benefit (603) (601) (1,659) (1,506) (11,898) Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary share-basic and diluted (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share-basic and diluted (0.34) (0.77) (2.07) (2.82) (2.88)	Total other income (expense)	677	181	1,225	550	292
Net loss (5,432) (2,976) (23,723) (13,409) (132,741) Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary shareholders (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted \$ (0.34) \$ (0.77) \$ (2.07) \$ (2.88)	Loss before taxes	(6,035)	(3,577)	(25,382)	(14,915)	(144,639)
Dividends on Preferred Ordinary shares — (2,967) (2,827) (8,910) (38,122) Net loss applicable to ordinary shareholders (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted (0.34) (0.77) (2.07) (2.88) (2.88)	Income tax benefit	(603)	(601)	(1,659)	(1,506)	(11,898)
Net loss applicable to ordinary shareholders (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted (0.34) (0.77) (2.07) (2.88)	Net loss	(5,432)	(2,976)	(23,723)	(13,409)	(132,741)
shareholders (5,432) (5,943) (26,550) (22,319) (170,863) Net loss per share – basic and diluted \$ (0.34) \$ (0.77) \$ (2.07) \$ (2.88)	Dividends on Preferred Ordinary shares		(2,967)	(2,827)	(8,910)	(38,122)
Net loss per share – basic and diluted \$ (0.34) \$ (0.77) \$ (2.07) \$ (2.88)						
	shareholders				(22,319)	(170,863)
Weighted average shares 16,157,991 7,761,453 12,806,491 7,761,453	Net loss per share – basic and diluted	\$ (0.34)	\$ (0.77)	\$ (2.07)	\$ (2.88)	
	Weighted average shares	16,157,991	7,761,453	12,806,491	7,761,453	

⁽¹⁾ Amounts include stock-based compensation, consisting of stock-based compensation expense under SFAS 123R, the amortization of deferred stock-based compensation and the value of options issued to non-employees

	months	For the three months ended September 30,		For the nine months ended September 30,	
	2006	2005	2006	2005	2006
	\$000	\$000	\$000	\$000	\$000
Research and development	164	(668)	6,052	103	7,918
General and administrative	93	(129)	3,262	76	3,950
	257	(797)	9,314	179	11,868

4

CYCLACEL PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

	As of September 30, 2006	As of December 31, 2005
	(Unaudited) \$000	\$000
ASSETS		
Current assets:		
Cash and cash equivalents	49,787	3,117
Short-term investments	9,951	10,690
Prepaid expenses and other current assets	3,219	3,219
Total current assets	62,957	17,026
Property, plant and equipment (net)	1,555	2,045
Deposits and other assets	259	_
Goodwill	2,749	_
Total assets	67,520	19,071
LIABILITIES AND STOCKHOLDERS EQUITY		
Current liabilities:		
Accounts payable	1,505	2,159
Amounts due to Cyclacel Group plc	_	10,467
Accrued liabilities	2,304	1,869
Other current liabilities	278	128
Derivative liability	1,389	_
Current portion of other accrued restructuring charges	879	_
Current portion of equipment financing	156	251
Total current liabilities	6,511	14,874
Other accrued restructuring charges, net of current	1,673	_
Equipment financing, net of current		78
Total liabilities	8,184	14,952
Commitments and contingencies		
Stockholders' equity:		
Preferred Ordinary shares, 0.1p par value; Nil and 21,000,000 shares authorized at		
September 30, 2006 and December 31, 2005 respectively; Nil and 17,965,835		
shares issued and outstanding at September 30, 2006 and December 31, 2005,		
respectively. Aggregate liquidation preference of \$Nil and \$210,954,000 (\$11.74		30
per share) at September 30, 2006 and December 31, 2005, respectively Ordinary shares, 0.1p par value; Nil and 5,748,428 shares authorized at September	_	30
30, 2006 and December 31, 2005 respectively; Nil and 1,871,210 shares issued and		
outstanding at September 30, 2006 and December 31, 2005, respectively	_	2
Preferred stock, \$0.001 par value; 5,000,000 shares authorized at September 30, 2006		_
and December 31, 2005, respectively; 2,046,813 and Nil shares issued and		
outstanding at September 30, 2006 and December 31, 2005, respectively.		
Aggregate preference in liquidation of \$20,673,000 and \$Nil at September 30,		
2006 and December 31, 2005, respectively	2	_
Common stock, \$0.001 par value; 100,000,000 and Nil shares authorized at		
September 30, 2006 and December 31, 2005, respectively; 16,157,991 and Nil		
shares issued and outstanding at September 30, 2006 and December 31, 2005,		
respectively	16	
Additional paid in capital	194,426	116,063
Accumulated other comprehensive loss	(2,367)	(2,958)
Deficit accumulated during the development stage	(132,741)	(109,018)
Total stockholders' equity	59,336	4,119
Total liabilities and stockholders' equity	67,520	19,071

SOURCE: Cyclacel Pharmaceuticals, Inc.

```
\label{lem:begin 644 html_04149logo.jpg M_IC_X``02D9)1@`!'0$!(`$@``#_@`V($EM86=E(&=E;F5R871E9"!B>2!'\\ M3E4@1VAO``$``@(#`0$!``````!P@!`P0&"04*`O_$`$40 M```&`@`"!P<"!`(""`,````!`@,$!08""!$2$Q=7E='6"10A,5%ADA5!%B(R MD0IQ&"4X0H&QP1DC)$=28G+PA:&F_\0`'0$!``$$`P$````````$"`B'*P$'"`$"`P$#!P,"!`0'`````$"`P$$04&$A,A06*1\"(C M,4)14M(''), ABC MD0IQ&"4X0H&QP1DC)$=28G+PA:&F_\0''0$!``$$`P$`````````$"`P$$`P$"`P$$04&$A,A06*1\"(C M,4)14M(''), ABC MD0IQ&"4X0H&QP1DC)$=28G+PA:&F_\0''0$!``$$`P$$```````````$"`P$$`P$#!P,"!`0'``````$"`P$$\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger{PA:\dagger
M<&Z]7_JD-F;98[&L$\VULU,.H0]89:_%.#)E1ED_"9D0D*GW)MI2_,KWZRDC M.=9>.$4"Q($6$?Q=IWA@FU.&U>#0U-\0/%/E'5,O17HZ>C,IJ.R;0:X?NK[<
MIJ\#5TZ>D4I@V*IV(IMZ]F>@OI]]/[\&9DY*W+URC=JSMH2J;4LRP)J<>L^R)" MQ\%32).60\#>F_2^Q[2F)2Q4SMW[\&"Q MOW?>WYZ1L.X\\EGO34W*3]
[5WGB&CH$R/[ZU3WV?8_@DM, M*0E2C;:QW$V9V1N]024I.+82')K9J(NDIWK!&-?6;@@2%R-?\9F"9':H2DS@ M,
 [KR"@E/G$=%AA&>QX5+*4I1\S:5,1S0D^9'TN@?W*G6.)W45_)\'U!D.W( MBY3KMENWB'S]>L\#R"6GG[[-IJ9JTI;*T@R'NL?CR+&ZG3.K+I2N;B3;3JE:
\label{eq:mp1} $$MP1=$LV.'S2FP.N(E:I_\land C;O*SFY;\%;4PIQ3K\%7,RS)U3G8J4*<0PYCMKV5>NV'V+74\_?^W)F:`F9.\EI_4GZ_P![[SNLJU\_6]]$
MV+>FZ7TQ15(5/QA\3NB[F'4[XQ)W*Z M.2HTL3IL&OJ)T]CDA1R,9S/'6G,1R%#39],FR9D]81]!V=%,R6CU!U%N3!-V
MXNC*L%M%2XS;B(EK6RT*BW%%9*90\JNMX*E*-EXDJZ3$AE3T">V1O0)4ADC6 M/?5V.WTTK"NTS>Q'\("VK5=7/WFM2]OT:::F6IM[ZC6@+S7EL^?
[2F9AYOGR9""DJJ.)#4FS+93C2D'&QJYP^AQ MNJL2,DN+D0ZN^KIBG'N1,Q/<9CYJ:*.\M'JBT+;3+VM>,-%:$RUZKP2#]?*K_`%LNPI/RKL&Y:[1N
ME].ES2&GGK3^E7T_MJT'9UJ5FV)BT_J5(?5KZL7]M&=D7&U"99M>_P#=N[5J M7FDY@.,6Q8MP/Y%:;;K)M">9\V#G-$YE^ M%X_=0>;,_'
%:E>FP,3:QW"WR_A^US3*6WG[&YARVXU=/?8DOP^1FO":XPY5 M3[%G5F7UR[*!`E2H.'U.B-A8_P"_38T1FYPW--?&F#8VT!:RTKZ+;H_
MI\22B4\VARZFM8[,#$*RI2@T2J5R?4VB5M)9=7=0["65K*=;2I9=*SF..VR' M26HI+%@U*2I27R,]N3:]Q7,K6DLLKJX\1L8])@6E117;3%KC<3):3(Z+*\9S M-
JCG,2(3>:8A>8_`GXEE+2$6V./*E.5C[#LA3Q=63GU/O3(VFXW9\RS*R4DM MR4E)=N5:04L))1_EIIH-3UFM/#O4RMDS"78;;4L.>I[$_A?^EMNW6E
M)F\%F3UIVW;3,I:MJ6@_:DT\')YY+4P46E9DTJ9L.\LU)'_*.VI>VRK>M>>4 MR'[1G9B9;94QY,LZTWYQF5N$66D]Y[$X:]+XAE&@=L8GQ8X]38[-VKQWX%^D MY8G9>I-U:'SA>%+ M$[S!>"3FO\'2V'9)FE_L*[QK7F.PL=J+#,,D6R=K>2(D-)(5*=8C0X,9""; MBUU9"@U57&@UD.-#:GM)$1%\3/X%\3,U&?W,S,S,_N9F8_ESGU:^7/GT3^7S M^0ZTG)R9GYAZ:FG2Z^^LK<5A0A-3X)0TTE#3+2``AIAEMMAEM*6F6VVTI0/3 M-CV-
9U@6;*6394L)61D64,,-9CSRR$CM.OS,RX]-3FYVRL*JPFQRBJ>06,6MT;6.7METZ
M.ON7KIE^`U1CV4ZJ.T]I5[;ZTV\TESBZJN+3%Z"I%35_&QPX[3X9]O19CF& M[0H2K/U>`I3608=DT"9%N<,V!B4QPR57Y7@>60*?*L=FH42&K*L;:=)R-
(DM M.8_9&A!KIK7PJ/2A\.=1KZ1L*K5J%`<---#ZUW\#P(I0ZQ]#B`XK-)\,KFI M8.VQ?I=X<:6T- MF<8/&YF|!M_=/LZ\QV9[,SA__2H=C&Q^-FNIX\&NX@^*^?7VCQ5Y;CXCY%MC M^.6-M`K:%:T MWII^VY^T4I6I8!20`NN$T!"<.AK0@DD@UK2E*>,>E>+>T9X3LR;X4W*'/,B4 M?&CF6P=?
Z`B76K-I8E:Y'E^K*:[O,\I,AHLPQ&@O29;A&'L5.K, M-;:=?F9ON7.K&#@^I<3AP&&9$^P5:YW?4IS8U;$F3_TJ/8O1HKRV>B(-#2@I
M7]Z[D16"1BQ&N$@:"GE2?"I\23OO2/JZ%]HIPB<3/$7Q$\*>F-KLY=O+A8LG M:K<^"C.5TR:"7#R"3B=M\D7EW35]'EL>CR>(]CUY+QF?9QJJV-B+*<2"W':#
(^)/;U!KE&86$BIP?'#A7V6;!V!:Q$,KF5NO=9814Y'L' M.9L%$B,Y9-XOC5FBJ9D,/VCL)AU+H_'QA?$'PP^SU>]DMQ`ZZK>)LMCZ-FSN M'?VCF>9]P?
 <6FE<>VK@'&58NY%M_:><;'V|I[$,3N)>M>+6[K,[Q>OR#+FK. M=&LSJ*5-H4:!$C^V.D'L2L_\0UQS)WA(HI.U,>X+.%'_`$%F;E^2[8M:#MSS ME?
$K:ZZ8GJ5$390[5_1H696..)1/.D6Q%4Z`J/&@))UBY>-^USX++_5._MP6&0[DP#&>&/!* MO9NY:S;?#'Q$:ER_&\"O7'VZ')ZW%-
A:WQZTR^NN3C/*A%B"+R4E!-N2X\5N M1%4_RN&GVL7"+Q9;0QG4>GE\04G*LOJ;6\H9N<\)?$KJW#)=9443V1R):\_V M)K+',,C-2JIGKZDY%TW^L..QHU9[U(E1FW8V]O#S_P"Q]]H7T>G_`+-.8\^L MZPT\O>Z?GT>E\.ET>?\`3\.?1,_@.-[.1GVJB*?3*^*JTX`17#7V$8<6/QM` M4O$=!W:5H>
(X<>"*N)>QK>; @*X2*CWTLO1\#CHD+M%1E4W4QB=; \$@)*2:?:I. MP_84) \land `R\land, 0HN!Q"0210\%=\$HW52O:6D@? \land `\#C(\land \&+S\land ?\%OHKC6U*UN[AU]) \land `R\land, 0HN!Q"(RAU) \land `RAU) \land `RAU) \land `RAU \land `RAU \land `RAU) \land `RAU \land `RAU \land `RAU) \land `RAU \land `RAU \land `RAU \land `RAU) \land `RAU \land `RAU \land `RAU \land `RAU \land `RAU) \land `RAU \land `RAU \land `RAU) \land `RAU \land `RAU) \land `RAU \land `
MRV5F>NGLLS3"$W,W&\BQ2262:_OY&-Y1!54Y/75=FA$&UBNLLS#B^ZSFNA*A MNNL+2L_D:^H>*.'N_;/8.68Q:Z?
EW67.X934L=B-)J<>=1!+'HUL;C+R\@\R5_M2\7'+DE2O_.2W^A' M\/G\?E\#^AC]$1M3`V?AD)Q:.H; MMX;D>/G%0VR@W5Q;*PEH);E7(6GD5;%[(?
9Q^Z3&M=I8;CTC%,FJK@VX4+>&MJ75]4S?0)3S917+J9.)E+Y.>[8SEDR\H;HX=3D$:T7.F?X'3[!HCIK1'[JH7)-%C%G/)!(191KV,XX[K7)9*$MMVN+Y)
(3C=TM+ MD2MF9)5=;!8[0L\U3;#*748W[0#+";1DFD!V;6_*2:9\6O9TN'&79]F?L]#3
M=X)&5?;M%$W*HO`P]AEDF1\MW@NDFYLXY*O%F1N\9R==NW;DT\9.QF)"U[85 M;SESKQVD6)V7L""T$93;7-N792JV9;VQY+R2D?J98M-
R\E*>-9%'R&*X]%-\^6S&-AA5PBND0*BWDFSTI4BB][ M<6_*KVG?\^[]Z0;T0W#ZJ/,F+;>6CLPKY>6--B%C7W&UL_=R7)6)1S<5P7%JR
M9$0N=T5,QUT.OJ65=95E5E'2\MI-C>2[:!`-93VXM,II4MN7,2M;VZIF;+(< M:=Q&;*>E+9HI5G$M+&)`)XR@+M7:\E5\:TD1R2_-KH4NRCU[BRC%92EI<66@MM2RC+LHM"7J9!]80T\L%EIYTXL29`S+PQ*O.H94E''')9; M_8EU;U_S'':=L''T<*+>DV5/S,FTI$Y-R/75A9TK+DV2ZQ!:6^YTI7X9N$[5O' M?
C>2XWK*SVW>IS')&LLR>]W-O7<&_,LM+MBLB4[#Q9/N',17+Z9,74P;%ZLB*8HJT MX]3`)"BAQFNL7TJW;K]DQP4;NW'D'$1-P?
8.J=\YA$BP,WV[PV,YW=PT9IGT M*&F,W&:V!+TEG>&5^'*D0 M$(`PA(PBNE!34U/,DU]:FL>9&QO9(<(&S]:Z`UCD+>_X\'ADRW/,[T_FU-Q5
M<0];N/'LOV8F:C-+^7NTM@0[5NY]PW93XQ+MWIMBIT[Q(XWQ78"U0?B1W70"53;GPW$I^'XE=*LMF9AD5C+H
M\;AV4NVJ,/D2E8Q%RAPLE*M5:H2\/18`J?4\X8$^T>G@/"@<sup>0</sup>/*^-*#45UUK$, M\0&@=6\3^E-F\/>ZL;+,-5;=Q"UPC.,==L+"`NPI+9"2=.'9P)#%C4VD-]MB M?
57-=(CV-5:18EC!?9E1VW$UNWE[,[@YXD-?Z2P'<>L+#*9'#C14%!I#9\+8 M6P\WUK>-CE564\*3C6^L'R;&]KPYTV-35CV0O'E*VLGG1&Y]]'GR^DU^X
M"1X\$Q)`/B*] = ?:/-2![*+A0;U/OW3>2R\land(O9V(\2V!UVL]JN;EXL\land(S<-W/P\ MBIDORZ\land CQJWV/L3(W, \0T_) = 5(FXBS46\%DGJ6K65.;C1DM?2X=?9AZ`X8=B8))
MILG7&PN+RTL<+JYU+0XOL[C3XF=M:V8K)E"[C;4.1K/86Q;["IK%55.I;H6I M5.XBB?C09=64:3!B.,^C("<20&IK]^J^AKXQ3EHT[*=/#LC36NFFG^U/["GC
MQK#V'?!7I657JU)D7&#K>EK:<0IMUI:3-*VW$J0I)F2DF1F0Y("02"""000002""* M4(.Q%!3["*5)2M*D+2%(4"E25`%*DD4((.A!&A!T(B)6]):^A.27<>KK3"U2
MU*6\W@>49-A<\QU1N+4\JHQRUKZ;BEGS4I7R&EK3509K389AM M6V8<;)M469M+,F(YI)72/I\%4V56ZOI\_*LG'5DI\\O+XGSF\!M_\0VZ:E5KV
86**G7F=U4*QRN)LC-< MLQ=]N[L[.KJ(=[--V!81*EUUBGAWBHKBVY,Q%.#(&<4SCG",:RE24T`6@80%!8"&P
MPIS1_I@J*2>PHZ:A/]5"<255`*112@8IF5SB9J62R%9"J9Z@A*DCO6QVNR5: MME:1@4G`2'55;0L1<3FKZI_`O,=$V;GL366"9-GEA`DVD+&:]-
A)@03CM2Y+ M:I4>*:&')*DL)61R"69N*(NB@R+XF0[V7]OL(CWMAEUL+4F=87CONGZWD-.B M#7'/D'$B$^FPAR#-
^0EIXVDI;969*ZI1&HDI^'2YE99"%/-)6B4TMI1NMI2MLU= MPYJ^J?P+S$1:6Q6;AN')HYV&T>$0LSU.'74&1RLEB6"U5]>R_=.S)4"N7&ES
MWX[A.0$LNML(:0I+[AK5T9=!W""%A&""#V:44*:>!QN5_P"M6\NT)=2U,-*< MKC*\5X@0<6]06F3_\-I'VW,.9OMW\%\TQ_7M)BEGF.77])8Y(S6P;&BI&6*6
ML?3&=>]]OYL1B5-??ZQ$:OB]-U2&G'GELM)Z0F%''UJ2E1I)!FE)F@R2HTF:2 M,TF:3-)FDS-)FDS29D?
($(58XD=69;M)FFK,5Q3$U6<1+3]3LNRRBQHLDP2R M*R:>D.U42LJWY-C$>AL),VBLFDG+7TO=B6TU(*S=;'?B5\&+*EN3Y,:'$C29 MSJ20[-
D,1VVGYCJ$_P`J7)3J5/N)3\$J69<_@+CB6@RPI!3F*QYB<6)6A!2H MT4I*0:X0DH0OLJ)Q)(,66%OF9FT.!1:26RRO#@;`4GM-C$VE:UI4,2EAQULA
M20G+4%)CG9F,FŚ MH6XZ[N@4VU)93CY357[<64^M34"8[%2A[JG'%);;Y&)D/_J7/E\R^\/S+[_3[ MBI.-ZDS-GB!7L]&/8OKJ@0QDC&1MXOD]A:O[.?
\`$9&%%S2HOJ1E_P#H M*]4'6W53"*$7G$O6T-QG#,K#+YW&=Z%#GQZ14A-A- MJVU3&4RG&EE+;,S-J(Z1'RLR2C47,C3^)]AN9[
MFF>UQTEBF7N?, YK,0MKN0>,97C,*J8@S4Y#6*AN0H^04\IL[#&I3S4E4622 ME&XDE()%Z4?$N?(RY_DHR-10RIE+"4LY!224
MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*)-<&\$''HU\BY-K7,B:2I(2X1X=B[;MS8Y3-\_CFMRR5.MGJ\SMXUA5T\#N/KJ6(S<=M!-N//3DSS=;<2AHVU)4:BI92T69A2\.8D-MC, HHJHK+:)!"BJAQE9J*, HHJHK+: 
EH$@:'%C(&-&(BB=ET)_H-3%
LI>+8HBO0K$E*A7M)![22DZBNJ5`*2?4$`CP($0I:;?FL;3?U718) M;Y):0,?I=9:E.'R4X@N9G;DOW_P`S^/U^/SY?L9_N7[?00D+[
MZ6DI8+6$E322Y16(X)*2H*!6K"0JHI@;W':&HQ)1F.["SO,\%JZZQB/X MG[PY$MII12K\HB5UQ)Q^XFT:&W%2%QJNZBN0)+CJ2(W#2:3(CY%*>1KNFZ&Y
M7CC$:3D":J>="FR/=(;MN<5Q->F5)ZMWJ(Y2E-J>=)IPTMI/HI-1D1U)P?0 M&?Z\R32N0UV31;]6-5=WC>>Q)K<&NZNDRHW+ZY_3)D6&4V_=9S&0[8,':/)>
M-!=E@P\ MVM; 6(\&9*4)5V\%K0TD`DA79"G'E984H!I(4,"B8NAS5]4\_@7F.O9; E\%=A>, 7^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_@7F.O9; E\%=A^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_@7F.O9; E\%=A^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_@7F.O9; E\%=A^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_@7F.O9; E\%=A^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_@7F.O9; E\%=A^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_@7F.O9; E\%=A^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4\_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-BNAS5]4_W^{M6W*G2JL}[1^{ODJBP}\&\%ON-
QV24GK'W>B3;*#4A!N+3TW&T=)9=@3\B_ MR_\`O]Q\/)F9T=$Z;G0>)WC+P M['&-=T-_/R.GQ".Q&=;FFQ8SXL/HO6;[A..1X;*(Z4,HZ2>DEM#5FQ=F`VEY
M8:*2V,.$IJ1JE)(J5.5(-0HA:DDUPG":18DUO.2S2WTK2ZÓ<86`%$A2@'%4"& MJ)6`%(2IM"TI("TA85$1;2VP6MI6$5K6,6656V?9&O&*2!63*FN,K$H1S&_>
 M)-N\_{C-M.12;9+-Q)(7\backslash 5F21)=/-L)} \\ ] ?!F654Y1V\$F,V[,IY\$B\%.?KGUD?3B\ M.S*]UZ\#) \\ 6U\backslash :L5UQE7/FA1D*Z\backslash 1VK,CV6O6;U\%24>21,1S"3>WU!>W;]\#\&MU.S^* \\ [NS+Q] ] $(1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.5) + (1.
MZQRJ5#]Q3/CPISS:GG5$2UMM=)I!=,B5\A/.(1)%?B]!`E4\+'GX-1!A+HZZ MQ8`%>J#K;JIA#FKZI_`O,.:OJG\"\P`*]4'6W53"'-7U3^!>8
H>!T/J8`%S+;]@YK^46LUW3O%;>5O?#P<1AVBSN[3:'@=# MZF#M%G=VFT/`Z'U,`!EM^P#B,.T6=W:;0\#H?4P=HL[NTVAX'0^I@`,MO
M5O?#P<1AVBS2^6L]H>!4/J8.T6=W:;0\#H?4P`&6W[!S7\H9KNG>*V\K>^'@ MXC#M%G=VFT/`J'U,,=HLWNSV?
X\%0^I@`,MOV\#FOY0S7=.\\ \ X\%0^I@[190=GM\#P^*A]3``9;?L'-?RAFNZ=XK;RM[X>\#B,.T6:7RUGM\#P^*A]A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A'A''+A''+A'A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''+A''
```

MP*A]3!VBSN[3:'@=#ZF``RV_8.:_E#-=T[Q6WE;WP\'\$8=HLWNSVAX%0^I@[M19W=IM#P.A]3``9;?L'-?RAFNZ=XK;RM[X>#B,.T6=W:;0\#H?

4P=HLWNSVA MX%0^I@`,MOV#FOY0S7=.\5MY6]\/!Q&':+.[M-H>!T/J8.T6=W:;0\#H?4P` M&6W[!S7\H9KNG>*V\K>^\'@XC#M%G=VFT/`Z'U,':+.[M-H>!T/J8*#+;]@YK M^4,UW3O%;>5O?#P<1C':+-[L]G_'Y_ZBH?4PSVBSN[3:'@5#ZF``RV_8.:_E M#-=T[Q6WE;WP\\\$8=HL[NTVAX'0^IACM\\$F]V>S__'J'U, \'!EM^P\#B, M8[1)O=GL_P`"H?4PSVBSN[3:'@=#ZF``RV_8.:_E#-=T[Q6WE;WP\\\$8=HL[MNTVAX'0^I@[19O=GM#X?+_45#\/_`F``RV_8.:_E#-=T[Q6WE;WP\\\$8=HL M[NTVAX'0^I@[19W=IM#P*A]3``9;?L'-?RAFNZ=XK;RM[X>#B,.T6;W9[0\"MP?4P=HL[NTVAX'0^I@],MOV#FOY0S7=.\5MY6]\/!Q&:+-[YZSV@?\^\"H? M4P=HLWNSVAX\%0^I@],MOV#FOY0S7=.\5MY6]\/!Q&:+-[M-H>!T/J8.T6=WM:;0\#H?4P^&6W[!S7\H9KNG>*V\K>^\@XC#M\%G=VFT/`Z'U,':+.[M-H>!T/MJ8*#+;]@YK^4,UW3O\%;>5O?#P<1AVBSN[3:'@=#ZF#M\%G=VFT/`Z'U,`!EM^MP#B,.T6=W:;0\#H?4P=HL[NTVAX'0^I@`,MOV#FOY0S7=.\5MY6]\/!Q& M':+.[M-H>!T/J8.T6=W:;0\#H?4P=HL[NTVAX'0^I@`,MOV#FOY0S7=.\5MY6]\/!Q& M':+.[M-H>!T/J8.T6=W:;0\#H?4P=HL[NTVAX'0^I@`,MOV#FOY0S7=.\5MY6]\/!Q& M':+.[M-H>!T/J8.T6=W:;0\#H?4P=HL[NTVAX'0^I@`,MOV#FOY0S7=.\5MY6]\/!Q& M':+.[M-H>!T/J8.T6=W:;0\#H?4P=HL[NTVAX'0^I@`,MOV#FOY0S7=.\5MY6]\/!Q& M':+.[M-H>!T/J8.T6=W:;0\#H?4P=HL[NTVAX'0^I@`,MOV#FOY0S7=.\5MY6]\/!Q& M':+.[M-H>!T/J8.T6=W:;0\#H?4P=HL[NTVAX'0^I@^,MOV#FOY0S7=.\5MY6]\/!Q& M':+.[M-H>!T/J8.TAPNO*(N-M-N-TAPNO*(N-M-N-TAPNO*(N-M-N-TA